<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03061227</url>
  </required_header>
  <id_info>
    <org_study_id>529_2016BO1</org_study_id>
    <nct_id>NCT03061227</nct_id>
  </id_info>
  <brief_title>Characterization of Metabolic and Brain Effects of Rising Glucagon During an Oral Glucose Challenge</brief_title>
  <official_title>Metabolic and Central Nervous System Characterisation of the Phenotype of Non-suppressed (Rising) Glucagon After Glucose Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators previously characterized a phenotype with non-suppressed glucagon at 120
      minutes after standardized oral glucose load. This phenotype is associated with healthy
      metabolic traits such as lower BMI, higher insulin sensitivity and lower liver fat content.
      Glucagon is a pleiotropic hormone that, besides its main action on increasing endogenous
      glucose production, also reduces appetite and increases basal energy expenditure. The aims of
      this study are to i. detect functional differences in the appetite-related central nervous
      system (CNS) areas between the suppressed and non-suppressed glucagon phenotype ii. mimick
      the non-suppressed glucagon phenotype in those participants who suppress glucagon by
      administering a very-low-dose glucagon infusion and retest them.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain activity</measure>
    <time_frame>change from baseline to 120 minutes after oral glucose challenge</time_frame>
    <description>Resting-state brain activity assessed by fMRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hunger rating</measure>
    <time_frame>before and 150 minutes after oral glucose challenge and start of glucagon/saline infusion</time_frame>
    <description>On visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain response to food cues</measure>
    <time_frame>before, 30 minutes and 120 minutes after oral glucose challenge and start of glucagon/saline infusion</time_frame>
    <description>Assessed by functional magnetic resonance imaging (fMRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>0-120 minutes</time_frame>
    <description>Assessed by 75 g oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>0-120 minutes</time_frame>
    <description>Assessed during 75 g oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal energy expenditure</measure>
    <time_frame>150 minutes after oral glucose challenge</time_frame>
    <description>Assessed by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hormone levels</measure>
    <time_frame>0-150 minutes</time_frame>
    <description>Change in adrenocorticotropic hormone (ACTH), growth hormone (GH), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle stimulating hormone (FSH), fibroblast growth factor 21(FGF-21) after oral glucose challenge and start of glucagon/saline infusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Intravenous glucagon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-dose glucagon infusion (0.5 pmol/min/kg body weight) over 150 minutes during a standardized 75 g oral glucose tolerance test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infusion over 150 minutes during a standardized 75 g oral glucose tolerance test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous glucagon</intervention_name>
    <description>Randomized application of glucagon or saline during oral glucose tolerance test</description>
    <arm_group_label>Intravenous glucagon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous saline</intervention_name>
    <description>Randomized application of glucagon or saline during oral glucose tolerance test</description>
    <arm_group_label>Intravenous saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 18.5- 29.9 kg/m2

          -  written informed consent

        Exclusion Criteria:

          -  Current

               1. febrile infection with temperatures&gt; 38.5 ° C in the last 14 days

               2. Blood donation within the last 12 weeks Pre-study Inclusion

          -  Chronic diseases:

               1. Diabetes mellitus

               2. Known liver diseases (hepatitisB/C, hemochromatosis, NASH)

               3. Chronic inflammatory diseases (rheumatoid arthritis, Crohn's disease, ulcerative
                  colitis) chronic renal insufficiency

               4. Cancer (known malignant disease)

               5. psychiatric diagnoses (bipolar disorder, schizophrenia, psychoses, depression,
                  agoraphobia)

               6. Persons with non-removable metal parts, e.g:

                    -  pacemaker

                    -  artificial heart valves

                    -  metal prostheses

                    -  implanted magnetic metal parts (screws, plates of operations)

                    -  spiral

                    -  metal slivers / garnet splinters

                    -  fixed braces

                    -  Acupuncture needle

                    -  Insulin pump

                    -  totally implantable venous access device (port)

                    -  tattoos, metallic eye shadows

               7. Persons with impaired sensitivity and / or increased sensitivity to heating of
                  the body

               8. Medical history of venous thromboembolism

               9. alcohol consumption of more than 50g / day

              10. In physical examination:

                  blood pressure &gt; 160/100 mmHg pathologic cardiac murmurs (diastolic or systolic
                  louder than 2/6)

              11. in the blood test: fasting glucose ≥ 125 mg/dl or HbA1c ≥ 6.5% AST or ALT&gt; 2.5x
                  upper limit of the reference range (&gt; 125 U/l) Hb &lt;12 g/dl C reactive protein
                  (CRP) &gt; 5 mg / dL or leukocytes&gt; 15000/μl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert Wagner, MD</last_name>
    <phone>+4970712982910</phone>
    <email>robert.wagner@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Heni, MD</last_name>
    <phone>+4970712980344</phone>
    <email>martin.heni@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Wagner, MD</last_name>
      <phone>+4970712982910</phone>
      <email>robert.wagner@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

